Zacks Small Cap Research on MSN4h
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...
Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...
Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...
Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short ...
Needham & Company LLC Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
NASDAQ:SRPT opened at $137.94 on Wednesday. The stock has a 50 day simple moving average of $122.16 and a 200 day simple moving average of $131.43. The stock has a market cap of $13.18 billion, a ...
Per the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the ...
SRPT stock opened at $130.50 on Monday. The firm’s 50-day moving average price is $121.80 and its two-hundred day moving average price is $131.40. Sarepta Therapeutics has a 12-month low of $78. ...
In trading on Tuesday, shares of Sarepta Therapeutics Inc (Symbol: SRPT) crossed above their 200 day moving average of $129.96, changing hands as high as $131.00 per share. Sarepta Therapeutics ...
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target lowered by Piper Sandler from $200.00 to $182.00 in a report issued on Wednesday,Benzinga reports.The brokerage currently ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing ...
Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sell recommendation. As of November 21, 2024, the average one-year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback